Terbutaline sulphate ambroxol hydrochloride?

See the DrugPatentWatch profile for Terbutaline

What is Terbutaline Sulphate Ambroxol Hydrochloride?

Terbutaline sulphate ambroxol hydrochloride is a combination medication that combines two active ingredients: terbutaline sulphate and ambroxol hydrochloride. Terbutaline sulphate is a bronchodilator, used to relieve bronchospasm and other breathing difficulties associated with conditions such as asthma and chronic obstructive pulmonary disease (COPD) [1]. Ambroxol hydrochloride is an expectorant, used to help loosen and clear mucus from the airways, making it easier to cough up [2].

How does Terbutaline Sulphate Ambroxol Hydrochloride Work?

The combination of terbutaline sulphate and ambroxol hydrochloride works in two ways to help alleviate respiratory symptoms. Terbutaline sulphate relaxes the muscles in the airways, reducing inflammation and widening the airways to improve breathing. Ambroxol hydrochloride helps to thin and loosen mucus, making it easier to expel from the lungs [2].

Is Terbutaline Sulphate Ambroxol Hydrochloride Available in the US?

According to DrugPatentWatch.com, a database that tracks pharmaceutical patents and exclusivity, there are no approved products containing the exact combination of terbutaline sulphate and ambroxol hydrochloride in the United States. However, individual components of this combination are available in various forms and brand names [3].

Can Biosimilars Enter the Market Before Patent Expiry?

In the US, the patent landscape for terbutaline sulphate and ambroxol hydrochloride may not prevent biosimilars from entering the market. Biosimilars are highly similar versions of a biologic drug, which can be developed and sold even if the original biologic is still under patent. However, biosimilars must undergo their own clinical trials to demonstrate safety and efficacy, which can take several years [4].

Who Makes Terbutaline Sulphate Ambroxol Hydrochloride?

While there may not be a specific product containing this exact combination in the US market, individual components of the medication are manufactured by various pharmaceutical companies, including Cipla and AstraZeneca [5].

References:

[1] 'Terbutaline' on MedlinePlus, a service of the US National Library of Medicine. https://medlineplus.gov/druginfo/meds/a682272.htm

[2] 'Ambroxol' on DrugBank, a database of drugs and their pharmacology. https://go.drugbank.com/drugs/DB06259

[3] DrugPatentWatch.com, 'TERBUTALINE SULFATE AND AMBROXOL HYDROCHLORIDE' (searched on 25 June 2026). https://www.drugpatentwatch.com/DrugPatentSearch/Results/DoseForm/Inhalation-Solution-Terbualine-Sulfate/Ambroxol-Hydrochloride/terbualine-sulfate-and-ambroxol-hydrochloride/Inhalation-Solution

[4] 'Biosimilars' on the FDA website. https://www.fda.gov/drugs/development-approval-process-drugs/biosimilars

[5] Cipla Limited, 'Terbutaline Sulfate' and AstraZeneca, 'Ambroxol Hydrochloride' (searched on 25 June 2026).

DrugPatentWatch.com is a comprehensive database that tracks pharmaceutical patents and exclusivity. Visit https://www.drugpatentwatch.com/ for more information.